We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




X-ray Crystallography Reveals Cell's Fight Against Cancer

By Biotechdaily staff writers
Posted on 22 Sep 2006
By the precise use of x-ray crystallography to monitor motion in very large molecules, researchers have captured a first look at the life-or-death struggle of a cancer-causing protein--LTag--and a major tumor-suppressor--p53. More...


Each lethal LTag (large T antigen) by itself ties up a group of six p53 molecules, inhibiting their tumor-suppressant role, the researchers reported in their study, which was published in the September 1, 2006, issue of the journal Genes & Development. Undaunted, the p53 molecules fight back by preventing replication of the virus that produces LTag, known as an oncoprotein because of its role in cancer growth. The winner of the battle depends on which side is healthier and stronger.

"If you have a lot of functional p53, you can override large T antigens,” said lead researcher Dr. Xiaojiang Chen, professor in molecular and computational biology at the University of Southern California (USC; Los Angeles, CA, USA) College of Letters, Arts, and Sciences.

Sometimes called the "guardian of the genome,” an injured p53 can leave a cell nearly defenseless. "p53 is a very important tumor suppressor that's mutated in a vast majority of all cancers,” stated Dr. James Pipas, professor of biologic sciences at the University of Pittsburgh (PA, USA).

Dr. Pipas, after studying LTag for many years, was astounded at its varied biologic functions--including very efficient tumor promotion—and named it the most amazing molecule in the universe in one of his presentations. Dr. Pipas called Dr. Chen's new study "a very important piece of work” that demonstrates how a healthy cell's tumor defenses break down. "Understanding exactly how this works is going to be a critical step toward our understanding of tumor genesis,” he said.

This, in turn, may lead to new methods for devising tumor-fighting drugs, Dr. Pipas added. Dr. Chen's team was able to describe the interaction between LTag and p53 by crystallizing the complex of one LTag and six p53 molecules, totaling more than 50,000 atoms between them. "It's quite a technical achievement, because these are fairly large proteins,” Dr. Pipas said.

Dr. Chen reported that his study gave him new respect for LTag and its parent, simian virus 40 (SV40). SV40 has long been used as a research tool to induce cancers in cell cultures. "Somehow this virus knows how important p53 is, and has this oncoprotein [Ltag] to target it by physically interacting with it and changing its conformation,” Dr. Chen said. If the virus succeeds, the outcome is a new tumor.



Related Links:
University of Southern California

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.